The European Union is increasingly adapting its vaccination strategy to mutations of the SARS-CoV-2 virus. Although the European Commission is now attempting to adjust its contracts for the advance purchase of vaccines to this new reality, it also intends to present its bio-defence pilot programme on Wednesday 17 February.
In an interview with the French newspaper Les Echos, published on Tuesday 16 February, Ursula von der Leyen, the President of the European Commission, said that the...